Owing to the high risk of hypoglycemia and reduced renal clearance in people with T2DM and chronic kidney disease (CKD), an insulin treatment that decreases glycated hemoglobin (HbA1c) without escalating the risk of hypoglycemia is clinically important. This evidence concerns the gene INS and type 2 diabetes mellitus.